Wednesday, July 8, 2026

Drug profile · INN

oxtriphylline

oxtriphylline (CHOLEDYL SA) is a phosphodiesterase 3 inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — oxtriphylline
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

oxtriphylline (CHOLEDYL SA) is a phosphodiesterase 3 inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN oxtriphylline
Brand CHOLEDYL SA
Mechanism Phosphodiesterase 3 inhibitor
Target Adenosine receptor
Route ORAL
Formulation TABLET, DELAYED RELEASE

Mechanism of action

Phosphodiesterase 3 inhibitor

Primary target: Adenosine receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. adenosine Adenosine receptor agonist
  2. aminophylline Adenosine receptor antagonist
  3. caffeine citrate Nervous system (N06)
  4. theophylline Phosphodiesterase 4 inhibitor
  5. caffeine Nervous system (N06)
  6. istradefylline Nervous system (N04)

Frequently asked questions

What is oxtriphylline?

oxtriphylline (CHOLEDYL SA) is a phosphodiesterase 3 inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for oxtriphylline?

CHOLEDYL SA is a marketed brand name for oxtriphylline. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of oxtriphylline?

oxtriphylline has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.